Retatrutide Cardiovascular Trial: 10,000-Patient Study

The retatrutide cardiovascular outcomes trial (CVOT) is the most ambitious study in the entire development program. Enrolling approximately 10,000 patients with obesity and established cardiovascular disease or high cardiovascular risk, this trial will determine whether retatrutide prevents heart attacks, strokes, and cardiovascular death. Phase 2 data showed significant improvements in cardiovascular risk markers alongside the unprecedented 24.2% weight loss (Jastreboff et al., NEJM 2023), but it takes a massive outcomes trial to prove these improvements translate to actual lives saved.

Why a Cardiovascular Outcomes Trial Matters

Cardiovascular disease is the leading cause of death worldwide, and obesity is one of its strongest modifiable risk factors. While weight loss improves cardiovascular risk markers (blood pressure, cholesterol, inflammation), the critical question is: does this improvement translate to fewer actual heart attacks and strokes?

The answer requires a CVOT — a massive, long-term trial that tracks real cardiovascular events. These trials are the gold standard of cardiovascular medicine and are often required or strongly encouraged by the FDA for metabolic drugs.

Trial Design

What SELECT Tells Us

Semaglutide's SELECT trial established the precedent for GLP-1-based cardiovascular risk reduction:

• 20% MACE reduction: Semaglutide reduced major cardiovascular events by 20% vs placebo
• Heart failure benefits: Significant reductions in heart failure hospitalization
• All-cause mortality: Trend toward reduced all-cause mortality

If semaglutide — a single agonist with 15-17% weight loss — achieved a 20% MACE reduction, retatrutide's 24%+ weight loss and additional metabolic benefits (glucagon-driven fat oxidation, liver fat reduction) could potentially produce even greater cardiovascular protection. This is the hypothesis the CVOT will test.

Why This Trial Changes Everything

• Beyond weight loss labeling: Positive CVOT results would allow retatrutide to carry a cardiovascular risk reduction claim — transforming it from a "weight loss drug" to a cardiovascular medicine
• Insurance coverage: Cardiovascular prevention is universally covered by insurance. A CVOT indication would dramatically expand coverage
• Treatment guidelines: Cardiologists would have evidence to prescribe retatrutide to high-risk patients specifically for cardiovascular protection
• Public health impact: If 10,000 patient-years of data confirm cardiovascular benefit, the public health implications for the billions worldwide with obesity-related cardiovascular risk are staggering

Proven Cardiovascular Benefits Available Now

Semaglutide already has proven cardiovascular benefits from the SELECT trial. Through TRIMI:

• Compounded semaglutide: $99/month — proven cardiovascular risk reduction
• Compounded tirzepatide: $125/month — significant cardiometabolic improvements

Learn more about how to get started.